RNA interference (RNAi) has recently been used for sequence-specific gene silencing of disease-related genes including oncogenes in hematopoietic cells. 
Introduction
RNA interference (RNAi) is widely being used as a powerful analytic tool for post-transcriptional gene silencing mediated by sequence-specific mRNA depletion. RNAi can be triggered by the delivery of doublestranded RNA (dsRNA) in the form of small interfering and small hairpin RNA (siRNA, shRNA), respectively. [1] [2] [3] [4] [5] [6] So far, no principle limitation to target any gene by RNAi has been described as long as sufficient sequence information is available. Accordingly, both foreign genes encoded by infectious organisms and fusion genes resulting from chromosomal translocation have been analyzed by RNAi. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] For example, short-term mRNA and protein reduction of the bcr-abl oncogene necessary for leukemic transformation in chronic myeloid and bcrabl+ acute lymphoblastic leukemia (CML, Ph+ALL), as well as inhibition of survival and proliferation of bcrabl+ cell lines have recently been described. [14] [15] [16] However, the application of RNAi for reverse genetics in mammalian cells is hampered by both the difficulty to deliver RNAi triggers to target cells and by the transient nature of RNAi in mammals. Recently, intracellular transcription of suitable dsRNAs upon gene transfer of pol III expression cassettes has been shown to overcome these limitations resulting in long-term and heritable, but still cell-autonomous gene silencing in mammalian cells. 4, 5, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Accordingly, a lentiviral gene transfer of shRNA has recently been reported in bcr-abl+ cell lines. 29 We here address whether RNAi may be exploited for therapeutic application besides its well-established value as an analytical tool for functional genomics. Targeting the bcr-abl oncogene by lentiviral gene transfer of antibcr-abl shRNA, we demonstrate a dose-response relation between multiplicity of lentiviral infection, bcr-abl gene silencing, and depletion of bcr-abl+ cells from suspension cultures. Importantly, we found a specific threshold of red fluorescence protein (RFP)-reporter gene expression and the number of lentiviral integrations required for permanent depletion of K562 cells by FACS analysis and quantitative PCR from genomic DNA of lentivirally transduced cells. In contrast to cells with high RFP expression, lentivirally transduced cells with lower RFPexpression levels and fewer lentiviral integrations can survive, but still show reduced bcr-abl mRNA levels, aberrant proliferation kinetics, and enhanced sensitivity to the Bcr-Abl-kinase inhibitor STI571. Interestingly, stable anti-bcr-abl RNAi, which is not sufficient to eradicate completely bcr-abl cells can still cooperate with STI571 in depleting bcr-abl+ cells. Finally, we demonstrate that lentivirus-mediated anti-bcr-abl RNAi can inhibit colony formation of primary bcr-abl+CD34+ cells from patients with CML to a similar extent as STI571. These data suggest that stable RNAi may indeed be used as a therapeutic for hematopoietic malignancies in the future. However, lentiviral gene transfer as a means to induce stable RNAi may harbor the risk of genotoxicity by insertional mutagenesis.
Results

Design of anti-bcr-abl shRNAs
Specific but transient inhibition of bcr-abl gene expression upon electroporation of the synthetic b3a2_1 siRNA targeting the b3a2-bcr-abl breakpoint region has been described recently (Figure 1a) . 15 To compare chemically synthesized siRNA with corresponding shRNA, which allows the subsequent study of stable RNAi, we first expressed a shRNA corresponding to b3a2_1 either from a conventional Blue-Script derived (not shown) or from a lentiviral transgene plasmid (Figure 1b) , which both harbor identical H1-RNA pol III-based transcription cassettes. In addition, a second asymmetric shRNA named b3a2_4 that completely matches both bcr-abl and human bcr mRNA was designed since the b3a2-fusion sequence encompasses a stretch of four adenosine residues, which have been reported to terminate pol III transcription ( Figure 1a) .
Normalized bcr-abl mRNA levels in K562 cells were analyzed by real-time RT-PCR either after electroporation of conventional or lentiviral plasmids (Figure 1c (Figure 1d ). b3a2_1 but not control shRNA reduced bcr-abl mRNA by about 75%, 48 h after electroporation, independent of the respective expression plasmid (Figure 1c) . Transduction of K562 cells with lentiviral supernatants resulted in a transduction efficiency of about 98% as determined by FACS analysis of RFP fluorescence (data not shown). Again, b3a2_1 but not control shRNA reduced bcr-abl, but neither bcr nor abl mRNA levels by about 95%, 5 days after lentiviral transduction (Figure 1d ). To analyze whether the lentiviral preparations used in this study induce an interferon response 2 0 5 0 -oligoadenylate synthetase (OAS1) mRNA levels were determined by quantitative RT-PCR. 30 Whereas treatment with a-IFN induced an increase in OAS1 mRNA levels by about 60%, transduction with both control and anti-bcr-abl shRNA encoding viruses did not change OAS1 mRNA Figure 1 siRNAs and lentiviral vectors. (a) The bcr-abl breakpoint region as well as sense and antisense strands of siRNA duplexes b3a2_1 and b3a2_4 are shown. The arrow marks the fusion between bcr (left) and abl (right) sequences of the b3a2 bcr-abl variant. (b) Schematic representation of the lentiviral transgene plasmids encoding shRNAs. The shRNA is transcribed from a human H1-RNA promoter inserted into the U3 region of the D3 0 -LTR of the lentviral vector to obtain a 'double-copy' (dc) vector. 27 The vector encodes either RFP or EGFP as marker gene driven by the SFFV-LTR promoter and harbors a central polypurine tract/central termination sequence (cPPT) and, in case of EGFP, a WPRE element for enhanced transgene expression. 5 0 -LTR HIV-1 5 0 -LTR; D3 0 -LTR HIV-1 self-inactivating (SIN) 3 0 -LTR; GA, deleted gag sequence; RRE, Revresponsive element; SD, splice donor site; SA, splice acceptor site; C, packaging signal. (c) Effects of shRNAs on bcr-abl mRNA in K562 cells. shRNAs were expressed either from conventional (pH1-shRNA, left) or lentiviral plasmids (pdcH1-shRNA-SR, right) containing identical H1-RNA transcription cassettes. Normalized bcr-abl mRNA levels were measured by real-time RT-PCR 48 h after electroporation and were expressed as % of mRNA levels of cells transfected with control GL4-shRNA. (d) Effects of lentivirus-mediated shRNA expression on bcr-abl, bcr, and abl mRNA in K562 cells. Normalized bcr-abl, bcr, and abl mRNA levels were measured by real-time RT-PCR 5 days after transduction and were expressed as % of mRNA levels of cells transfected with control GL4-shRNA. (e) Normalized OAS1 mRNA levels in K562 cells 18 h after treatment with a-interferon (100 U/ml) or lentiviral transduction with control and b3a2_1 shRNAs, respectively. To analyze the effects of b3a2_1 siRNA and shRNA on bcr-abl-dependent cell proliferation, K562 cells were first electroporated with synthetic b3a2_1 and control siRNAs (Figure 2a) or with b3a2_1 and control shRNA expressed either from conventional or lentiviral plasmids, respectively (Figure 2b) . Electroporation of K562 cells with chemically synthesized b3a2_1 siRNA or with conventional or lentiviral plasmids expressing corresponding shRNAs but not control si/shRNAs induced a significant but only transient reduction of viable cell numbers on day 4 (up to 7575%). Next, we transfected K562 cells with specific and control lentiviral supernatants generated with identical lentiviral transgene plasmids used for electroporation as described above. This strategy allows the monitoring of transduced cells by analysis of RFP fluorescence. With a transduction rate of 498% as determined by FACS analysis (data not shown), we observed an almost complete depletion of K562 cells up to 10 days after transduction (Figure 2c ). In particular, cultures of b3a2_1 shRNA-transduced cells stopped growing at day 3, and the number of viable cells declined beginning at day 4 after lentiviral transduction (data not shown, three independent experiments).
Dose-dependent inhibition of cell proliferation by lentivirus-mediated RNAi
To study the impact of lentiviral dose on cell proliferation, K562 cells were transduced at four different multiplicities of infection (MOI), namely MOI ¼ 0.2, 1, In K562 cells transduced with control and anti-bcr-abl shRNA lentiviruses at MOIs of 0.1, 0.5, 2.5, and 5, the transduction efficiency ranged between 95 and 91% RFP+ cells for MOIs of 5 and 2.5, and 61 and 16% RFP+ cells for the MOI of 0.5 and 0.1 as determined by FACS analysis 72 h after transduction (data not shown). Southern blot analysis of genomic DNA revealed an increasing number of proviral integrations at higher MOI (data not shown). In addition, real-time PCR of genomic DNA isolated from K562 cells transduced at MOIs of 0.1, 0.5, 2.5, and 5 using RFP-specific primers and TaqMan probes demonstrated increasing RFP/HCK ratios of about 0.1, 0.5, 3, and 4 with increasing MOI (Figure 4a ). To validate quantitative PCR from genomic DNA and to normalize DNA input, we quantified endogenous HCK and albumin copy numbers with HCK/albumin ratios between 1.0 and 1.9 found in all samples analyzed.
To study b3a2_1 siRNA expression, total RNA from U937 cells transduced at different MOIs was isolated 12 days after lentiviral transduction and siRNA expression was analyzed by Northern blotting using U6 small nuclear RNA as loading control. As shown in Figure 4b , cultures of U937 cells transduced at high MOIs (5 and 10) express the highest siRNA level, whereas cells transduced at lower MOIs (0.2 and 1) exhibit lower amounts of anti-bcr-abl siRNA.
Since some b3a2_1-transduced K562 cells with low RFP-MFI could be recovered after prolonged culture periods (Figure 3b ), lentiviral integration numbers were determined in K562 cultures transduced at different MOIs over time. The transduction efficiency ranged between 20 and 70% RFP+ cells using an MOI of 0.2 and 1, whereas 99% RFP+ cells were found after lentiviral transduction at MOIs of 5 and 10 (data not shown). Southern blot analysis using a human H1-promoterspecific probe and RFP-specific real-time PCR of genomic DNA (Figure 4c ) demonstrated an MOI-dependent increase in proviral integrations up to RFP/HCK ratios 410, 5 days after transduction. In contrast to analyses performed shortly after lentiviral transduction, cultures recovered 3 weeks after transduction showed a relative decrease in proviral integrations as analyzed by both Southern blotting and real-time PCR. Different to K562 cells, a similar pattern as that found in K562 cells at day 5 but no change in lentiviral integration number over time 
Further characterization of surviving anti-bcr-abl shRNA-transduced K562 cells
Having demonstrated a decrease in RFP-fluorescence intensity and the number of lentiviral integrations in b3a2_1 shRNA-transduced K562 cells recovered after prolonged cell culture (Figures 3b and 4c) , bcr-abl mRNA levels were analyzed by Taqman RT-PCR in these cells. As shown in Figure 5a , RNA isolated at day 21 showed a smaller reduction in bcr-abl mRNA levels by only B30% compared to RNA isolated at an earlier time point (day 5). In addition, proliferation kinetics of surviving b3a2_1 shRNA expressing K562 cells was delayed as compared to parental or control shRNA-expressing cells (data not shown). Finally, anti-bcr-abl shRNA K562 cells showed a slight but consistent increase in STI571-induced cell killing as compared to control-transduced or parental K562 cells (Figure 5b ). (Figure 1b) . Subsequently, seven individual clones of TonB/dcH1-b3a2_4-SEW cells with different levels of EGFP fluorescence were isolated by limiting dilution in the presence of murine IL-3 (Table 1, 
Effects of lentivirus
-mediated anti-bcr-abl shRNAs on murine TonB cell proliferation Since the data described so far suggest clonal evolution of lentivirally transduced K562 cells, we analyzed doseresponse effects on individual clones of transduced murine TonB cells. This system allows clonal isolation of transduced cells by culture in the presence of murine interleukin-3 (IL-3) and subsequent analysis of Bcr-Abl function in the absence of cytokine stimulation. TonB cells were transduced with supernatants of b3a2_4 shRNA and control lentiviruses, and lentiviral transduction was monitored for EGFP expression
Effects of lentivirus-mediated anti-bcr-abl shRNAs on primary CD34+ CML cells
Transfection of primary CML cells with chemically synthesized b3a2_1 siRNA induced a reduction of bcrabl mRNA levels, but had no detectable effects on colony formation of CML progenitors in an earlier study. 15 Since this may be due to the transient nature of RNAi triggered by exogenous application of siRNA in proliferating cells, we lentivirally transduced primary CD34+ CML cells. After transduction cells were plated in methylcellulose cultures in the presence of high or low concentrations of GM-CSF and IL-3. We hypothesized that proliferation of early chronic phase CML colony-forming cells (CFU) is supported by signals delivered from both cytokine receptors and the Bcr-Abl oncoprotein. In accordance with this, STI571 inhibits colony formation of CD34+ CML but not normal CD34+ cells in a dose-dependent manner under optimal cytokine stimulation (Table 2a) . Similarly, the ratio of RFP+ colonies which are derived from progenitors transduced with dc-H1b3a2_1-SR but not with dc-H1GL-4-SR or dc-H1121GFP-SR decreases by about 50-60% under low as opposed to high cytokine stimulation (Table 2b ). In contrast to CML cells, colony formation of transduced normal CD34+ was not inhibited by anti-bcr-abl RNAi.
Discussion
We analyzed the potential therapeutic value of RNAi in the bcr-abl model using lentiviral gene transfer of antibcr-abl shRNAs. We first compared different modes to induce anti-bcr-abl RNAi and studied some basic pharmacokinetic aspects of lentivirus-mediated RNAi in bcr-abl+ cell lines. Both anti-bcr-abl siRNA and shRNA induce a specific but only transient inhibition of cell proliferation after electroporation of K562 cells. In contrast to transfection by electroporation, lentiviral gene transfer of the identical H1-shRNA expression cassette mediates extensive cell death and depletion of bcr-abl+ cells from cell cultures. This inhibition is specific and Recently, the heterogeneity of cell populations in terms of number of lentiviral integrations and reporter gene expression after lentiviral transduction at a given MOI has been described. 27 In the present study, the RFPfluorescence intensity in cells transduced with anti-bcrabl shRNA lentiviruses varies about 1000-fold as quantitated by FACS analysis. Whereas this pattern remains unchanged over time in bcr-ablÀU937 cells, RFP expression was significantly reduced, and RFP-highexpressing cells were no longer detectable in anti-bcr-abl shRNA-transduced K562 cells that could be recovered about 3 weeks after lentiviral transduction. Furthermore, Southern blot analysis and/or quantitative PCR of genomic DNA demonstrated a reduction of lentiviral integrations after prolonged periods of culture as compared to the cell population immediately after lentiviral transduction. Interestingly, such cells still have reduced bcr-abl mRNA levels as determined by TaqMan RT-PCR, display delayed cell proliferation kinetics as compared to controls, and are more sensitive to STI571 than control-or nontransduced cells. Using our lentiviral preparations, we found a threshold of more than a mean of three proviral integrations required to eradicate and prevent recovery of transduced K562 cells. This threshold may depend on both the vector design as well as the efficacy of individual sh/siRNAs. [31] [32] [33] In particular, careful evaluation of the optimal pol III promotor, such as the H1 or U6 promoter, to drive shRNA expression in hematopoietic cells as well as optimization of shRNA design to improve shRNA processing 34, 35 and antisensestrand incorporation into RISC [31] [32] [33] may provide more efficient tools to deplete sufficiently the Bcr-Abl oncoprotein at a lower number of lentiviral integrations into the target cell genome.
To avoid clonal selection of transduced cells, we analyzed dose-response effects on the clonal level in the murine TonB model. Again, when these clones were analyzed according to reporter gene MFI, a correlation was found between GFP-expression level and cell death in the absence of murine IL-3. Interestingly, anti-bcr-abl shRNAs cooperated with the protein antagonist STI571 with a correlation between GFP-expression level and both the time and extent of TonB cell depletion being Number RFP+ colonies/Total colony number (%) 20 ng/ml GM-CSF 0.25 ng/ml GM-CSF CD34+ 10 ng/ml IL-3 0.125 ng/ml IL-3
Stable RNAi against bcr-abl M Scherr et al observed. These data are in line with a recent study reporting the sensitization to the effects of STI571 by antibcr-abl RNAi in a transient electroporation model. 16 Stable RNAi targeting bcr-abl gene expression not only inhibits cell survival and proliferation in cell lines but also inhibits colony formation of CD34+ CML cells. We used colony growth of RFP+-transduced progenitors under suboptimal cytokine stimulation to probe for functional silencing of the Bcr-Abl oncoprotein in primary CML cells. In an earlier study, we found reduction of bcr-abl mRNA but no effects on colony formation of primary CML progenitors upon electroporation of chemically synthesized siRNAs. 15 The present study clearly indicates that stable but not transient RNAi might be useful to inhibit specifically oncogenedriven cell proliferation in primary hematopoietic cells.
Taken together, our data suggest that stable RNAi fulfils some prerequisites for a future therapeutical application in hematopoietic cells. First, gene silencing seems to depend on the dose of the RNAi trigger applied to target cells. Second, an efficient threshold for therapeutic effects may be defined at least in the bcrabl model analyzed here. And finally, stable RNAi can be induced in primary malignant hematopoietic cells and can result in specific inhibition of clonal expansion of transformed cells.
However, if a strategy based on virus-mediated integration of shRNA expression cassettes into the host cell genome is used, the viral dose used for cellular transduction may not be increased without upper limits since the number of proviral integrations may correlate with the risk for insertional mutagenesis in both target and normal bystander cells. 36 Therefore, it will be important either to generate alternative ways to induce stable RNAi or to generate more effective self-inactivating gene silencing vectors improved for high expression of one or more optimized shRNAs to reduce potential genotoxic side effects. Furthermore, the vector dose required for effective gene silencing may also depend on the individual target sensitivity. Finally, oncogene expression can be targeted on the mRNA and protein level, and both strategies can efficiently be combined as shown here with the protein antagonists STI571 in the bcr-abl model.
Materials and methods
shRNA synthesis and construction of H1-shRNA expression cassette
Oligonucleotides encoding two different shRNAs covering the fusion sequence of the b3a2 variant of the bcr-abl gene (b3a2_1 and b3a2_4 according to Scherr et al, 15 Figure 1a) were chemically synthesized including overhang sequences from a 5 0 BglII and a 3 0 SalI restriction site for cloning purposes (BioSpring, Frankfurt, Germany). b3a2_4 targets both bcr-abl and c-bcr, but its expression should not be hampered by the stretch of four adenosine residues at the breakpoint sequence. The oligonucleotide sequences were as follows: FPb3a2_1 -
0 -GATCCCCGATTTAAGCAGAGTTCAAATT CAAGAGATTTGAACTCTGCTTAAATCTTTTTTGGAA G-3'; and RPb3a2_4 -5 0 -TCGACTTCCAAAAAAGATT TAAGCAGAGTTCAAATCTCTTGAATTTGAACTCTGCT TAAATCGGG-3 0 . The noncomplementary 9 nt loop sequences are underlined, and each sense oligonucleotide harbors a stretch of T as pol III transcription termination signal. Corresponding oligonucleotides were annealed and inserted 3 0 of the H1-RNA promoter into the BglII/ SalI-digested pBlueScript-derived pH1 plasmid to generate pH1-b3a2_1 and pH1-b3a2_4 as described. 27 The control pH1-GL4 and control GL2 and GL2inv siRNAs have been described earlier. 15, 27 Construction of lentiviral vectors pdc-SR and pdc-SEW (pdc: plasmids resulting in doublecopy proviruses) were used to generate lentiviral transgenic plasmids containing H1-siRNA expression cassettes located in the U3 region of the D3 0 -LTR. 27 To generate lentiviral pdcH1-siRNA-SR and pdcH1-siRNA-SEW plasmids, the pH1-b3a2_1 and pH1-b3a2_4 plasmids were digested with SmaI and HincII and the resulting DNA fragments (360 nt) were blunt-end ligated into the SnaBI site of either pdc-SR or pdc-SEW to generate pdcH1-b3a2_1-SR and pdcH1-b3a2_4-SEW, respectively ( Figure 1b) . A H1-RNA cassette without any functional shRNA gene was ligated into the 3 0 DU3-LTR resulting in pdcH1-SEW. All lentiviral constructs encode RFP EXPRESS (SR) or EGFP (SEW) as reporter gene, respectively.
Cell culture
The 293T cells were grown at 371C in Dulbecco's modified Eagle's medium, 10% FCS, and 2 mM Lglutamine. Hematopoietic cell lines K562 and U937 were maintained in RPMI 1640 with 10% FCS. TonB cells, a murine pro-B-cell line dependent either on IL-3 or doxycycline-inducible expression of Bcr-Abl for survival and proliferation, 37 were cultured in RPMI 1640 supplemented with 10% FCS and mIL-3 (supplied as 10% conditioned medium from Wehi3B cells).
CD34+ cells from CML patients (b3a2 variant) in first chronic phase were isolated at the time of initial diagnosis as described. 38 Purification resulted in X98% purity.
Transfection by electroporation
The transfection of chemically synthesized siRNA and shRNA expression vectors into K562 cells were carried out as described previously. 15 RNA expression and the number of viable cells were analyzed from 48 h up to 7 days, respectively.
Preparation of recombinant lentiviral supernatants and lentiviral transduction VSV.G-pseudotyped lentiviral particles were generated by calcium phosphate cotransfection of 293T cells, and viral supernatants were concentrated as described previously.
28 dcH1-shRNA-SR and dcH1-shRNA-SEW lentiviral preparations were titered in triplicate by serial dilutions of the concentrated vector stocks on both 1 Â 10 5 U937 and K562 cells in 24-well plates. The number of RFP+ and EGFP+ cells was analyzed 72 h post-transduction by FACS analysis (FACS-Calibur, Stable RNAi against bcr-abl M Scherr et al Becton-Dickinson), and the titers were averaged and typically ranged between 5 and 10 Â 10 7 IU/ml. Lentiviral supernatants were used to transduce (i) K562, (ii) U937, (iii) TonB cell lines and, (iv) CD34+ CML cells as described recently. 38 The cell lines were transduced with an MOI as indicated in the figure legends and the CML CD34+ cells were transduced with an MOI of 2. At 2 days post-transduction, cells were either expanded as bulk populations or sorted (Cytomation, Freiburg, Germany) according to RFP and GFP expression, respectively, and individual clones were isolated. Colony assays of transduced CD34+ CML cells were performed as described earlier, but cultures were stimulated with human IL-3 and GM-CSF at either 10 and 20 ng/ml (high stimulation) or 0.25 and 0.125 ng/ml (low stimulation), respectively.
Real-time RT-PCR
Cytoplasmatic RNA was isolated using the RNeasy mini spin columns (Qiagen, Hilden, Germany) from 1 Â 10 6 K562 and U937. RNA was reverse transcribed into cDNA in a total volume of 20 ml using the MMLV reverse transcriptase (Invitrogen, Groningen, Netherlands) and random hexamer primers under standard conditions. Real-time Taqman RT-PCR of bcr-abl, bcr, abl, and GAPDH was performed as described previously. 15, 39 Quantitative RT-PCR of OAS1 expression in K562 cells was analyzed using the following primers: OAS1-FP, 5
0 -AGGTGGTAAAGGGTGGCTCC-3 0 ; OAS1-RP, 5 0 -ACAA CCAGGTCAGCGTCAGAT-3 0 , and the FAM-labeled probe, 5 0 -CAGGCAAGGGCACCACCCTC-3 0 . Each sample was run in triplicate, and average Ct values for OAS1 were normalized to Ct values for GAPDH.
Proliferation assay
Cell proliferation was analyzed by trypan blue exclusion assay. Briefly, 1-5 Â 10 4 K562 cells/ml were grown in 24-well plates. Cell numbers were analyzed after 24 h and up to 40 days by trypan blue exclusion.
Real-time PCR of genomic DNA Genomic DNAs were isolated from transduced K562 and U937 cells using the QIAamp kit (Qiagen). To quantify proviral integration, DNA was amplified using RFPspecific primers RFP-FP 5 0 -GCCCTTCGCCTGGGACAT-3 0 and RFP-RP 5 0 -GGTGCTTCACGTACACCTTGGA-3 0 , and quantitated using the FAM/TAMRA-labeled RFPspecific Taqman probe 5 0 -CTGTCCCCCCAGTTCCAG TACGG-3 0 . For normalization of DNA input, we quantified endogenous albumin and HCK copy numbers using PCR primers and VIC/TAMRA-labeled Taqman probes as described. 40, 41 Standard curves were generated using dilutions of plasmid DNA (2 Â 10 2 to 2 Â 10 7 copies/ reaction) with a correlation coefficient 498% for each analysis.
Southern blot analysis
In all, 15 mg of genomic DNA were digested overnight with EcoRI, extracted with phenol-chloroform, precipitated in ethanol, and quantified by UV spectrophotometry. In total, 10 mg were separated by electrophoresis on a 1% agarose gel and transferred to a Hybond-N+ membrane (Amersham-Pharmacia Inc.) according to standard procedures. 42 A 32 P-labeled human H1-RNA promoter DNA probe was used for hybridization, and visualization was performed by autoradiography.
Northern blot analysis
Total RNA from transduced U937 and K562 cells was isolated using Trizol according to the manufacturer's instruction (Invitrogen). RNA (10 mg) was subjected to electrophoresis on a 10% denaturing polyacrylamide gel, and transferred by electroblotting onto Hybond-N+ membrane (Amersham-Pharmacia). The hybridization and washing steps were carried out at 371C. Membranes were probed with a 32 P-labeled bcr-abl oligonucleotide and visualized by autoradiography. The sequence of the radiolabeled 19-mer sense DNA probe was: b3a2_1S -5 0 -GCAGAGTTCAAAAGCCCTT-3 0 . The endogenous human U6 snRNA served both as internal standard and loading control (U6sn: 5 0 -TATGGAACGCTTCACGA ATTTGC-3 0 ).
